Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 29Myelodysplastic Syndromes 10Advanced Solid Tumors 8Leukemia, Myelomonocytic, Chronic 6Myeloproliferative Disorders 5Advanced Solid Tumor 5Ovarian Neoplasms 4Neoplasms 4Multiple Myeloma 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumour 4Small Cell Lung Carcinoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Monocytic, Acute 3Triple Negative Breast Neoplasms 2Thrombocythemia, Essential 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Primary Myelofibrosis 2Polycythemia Vera 2Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Acute 2Leukemia, Biphenotypic, Acute 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Breast Neoplasms 2

Interventions

pertuzumab 5Trastuzumab 5Docetaxel 3tucatinib 2pyrotinib 1atezolizumab 1Paclitaxel 1Neoadjuvant Therapy 1Injections 1Genetic Testing 1Carboplatin 1Capecitabine 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Injections × 90 days × Clear all
NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
544 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡